148 related articles for article (PubMed ID: 38011421)
21. Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study.
Manchon E; Laplaud D; Vukusic S; Labauge P; Moreau T; Kobelt G; Grouin JM; Lotz M; Pau D; Christine LF
Mult Scler Relat Disord; 2022 Dec; 68():104109. PubMed ID: 36007299
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study.
Alcalá C; Gascón F; Pérez-Miralles F; Gil-Perotín S; Navarré A; Boscá I; Coret F; Casanova B
J Neurol; 2018 Jul; 265(7):1690-1697. PubMed ID: 29785523
[TBL] [Abstract][Full Text] [Related]
23. COVID-19 outcomes in persons with multiple sclerosis treated with rituximab.
Iyer RB; S R; M JN; R J
Mult Scler Relat Disord; 2022 Jan; 57():103371. PubMed ID: 35158435
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis - A cohort study.
Torgauten HM; Myhr KM; Wergeland S; Bø L; Aarseth JH; Torkildsen Ø
Mult Scler J Exp Transl Clin; 2021; 7(1):2055217320973049. PubMed ID: 33796328
[TBL] [Abstract][Full Text] [Related]
25. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis.
Boremalm M; Juto A; Axelsson M; Novakova L; Frisell T; Svenningsson A; Lycke J; Piehl F; Salzer J
Eur J Neurol; 2019 Aug; 26(8):1060-1067. PubMed ID: 30762259
[TBL] [Abstract][Full Text] [Related]
26. Profile of Polish patients with primary progressive multiple sclerosis.
Brola W; Sobolewski P; Żak M; Flaga S; Fudala M; Siutka D; Kapica K; Chorąży M; Kułakowska A; Perenc A; Bartosik-Psujek H; Psujek M; Głąbiński A; Pawełczyk M; Gacek S; Potemkowski A
Mult Scler Relat Disord; 2019 Aug; 33():33-38. PubMed ID: 31146082
[TBL] [Abstract][Full Text] [Related]
27. Rituximab for the treatment of multiple sclerosis: a review.
Chisari CG; Sgarlata E; Arena S; Toscano S; Luca M; Patti F
J Neurol; 2022 Jan; 269(1):159-183. PubMed ID: 33416999
[TBL] [Abstract][Full Text] [Related]
28. The Rao's Brief Repeatable Battery in the study of cognition in different multiple sclerosis phenotypes: application of normative data in a Serbian population.
Dackovic J; Pekmezovic T; Mesaros S; Dujmovic I; Stojsavljevic N; Martinovic V; Drulovic J
Neurol Sci; 2016 Sep; 37(9):1475-81. PubMed ID: 27207679
[TBL] [Abstract][Full Text] [Related]
29. Genetic differences between primary progressive and relapsing-remitting multiple sclerosis: The impact of immune-related genes variability.
Kiselev I; Bashinskaya V; Baulina N; Kozin M; Popova E; Boyko A; Favorova O; Kulakova O
Mult Scler Relat Disord; 2019 Apr; 29():130-136. PubMed ID: 30711878
[TBL] [Abstract][Full Text] [Related]
30. Ocrelizumab treatment in multiple sclerosis: A Danish population-based cohort study.
Pontieri L; Blinkenberg M; Bramow S; Papp V; Rasmussen PV; Kant M; Schäfer J; Mathiesen HK; Jensen MB; Sirakov G; Berg JM; Kopp TI; Joensen H; Sellebjerg F; Magyari M
Eur J Neurol; 2022 Feb; 29(2):496-504. PubMed ID: 34644452
[TBL] [Abstract][Full Text] [Related]
31. Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review.
Castillo-Trivino T; Braithwaite D; Bacchetti P; Waubant E
PLoS One; 2013; 8(7):e66308. PubMed ID: 23843952
[TBL] [Abstract][Full Text] [Related]
32. Experience with rituximab therapy in a real-life sample of multiple sclerosis patients.
Bellinvia A; Prestipino E; Portaccio E; Razzolini L; Fonderico M; Fratangelo R; Tudisco L; Pastò L; Amato MP
Neurol Sci; 2020 Oct; 41(10):2939-2945. PubMed ID: 32350672
[TBL] [Abstract][Full Text] [Related]
33. Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive multiple sclerosis.
Ratzer R; Søndergaard HB; Christensen JR; Börnsen L; Borup R; Sørensen PS; Sellebjerg F
Mult Scler; 2013 Dec; 19(14):1841-8. PubMed ID: 24085340
[TBL] [Abstract][Full Text] [Related]
34. Clinical course of multiple sclerosis and labour-force absenteeism: a longitudinal population-based study.
Castelo-Branco A; Landfeldt E; Svedbom A; Löfroth E; Kavaliunas A; Hillert J
Eur J Neurol; 2019 Apr; 26(4):603-609. PubMed ID: 30414299
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of rituximab in relapsing-remitting multiple sclerosis: A systematic review and meta-analysis.
Tian X; Chen C; Ma L; Wei R; Li M; Wang X; Wu Y; Zhou Y; Cui Y
J Neuroimmunol; 2020 Oct; 347():577317. PubMed ID: 32731048
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Rituximab in Central Nervous System Demyelinating Disorders.
Patil VA; Kamat SN; Lalkaka JA; Singhal B
Ann Indian Acad Neurol; 2021; 24(5):732-739. PubMed ID: 35002132
[TBL] [Abstract][Full Text] [Related]
37. Estimating the disutility of relapse in relapsing-remitting and secondary progressive multiple sclerosis using the EQ-5D-5L, AQoL-8D, EQ-5D-5L-psychosocial, and SF-6D: implications for health economic evaluation models.
Ahmad H; Campbell JA; van der Mei I; Taylor BV; Xia Q; Zhao T; Palmer AJ
Qual Life Res; 2023 Dec; 32(12):3373-3387. PubMed ID: 37522942
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience.
D'Amico E; Zanghì A; Chisari CG; Fermo SL; Toscano S; Arena S; Patti F; Zappia M
Mult Scler Relat Disord; 2019 Jan; 27():324-326. PubMed ID: 30471585
[TBL] [Abstract][Full Text] [Related]
39. Cervical cord area is associated with infratentorial grey and white matter volume predominantly in relapsing-remitting multiple sclerosis: A study using semi-automated cord volumetry and voxel-based morphometry.
Bellenberg B; Schneider R; Weiler F; Suchan B; Haghikia A; Hoffjan S; Gold R; Köster O; Lukas C
Mult Scler Relat Disord; 2015 May; 4(3):264-72. PubMed ID: 26008944
[TBL] [Abstract][Full Text] [Related]
40. Self-reported changes in the expanded disability status scale score in patients with multiple sclerosis after autologous stem cell transplants: real-world data from a single center.
Ruiz-Argüelles GJ; Olivares-Gazca JC; Olivares-Gazca M; Leon-Peña AA; Murrieta-Alvarez I; Cantero-Fortiz Y; Gomez-Cruz GB; Ruiz-Argüelles A; Priesca-Marin M; Ruiz-Delgado GJ
Clin Exp Immunol; 2019 Dec; 198(3):351-358. PubMed ID: 31394007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
